Prevymis (letermovir) - Merck (MSD)
Rethinking Letermovir Strategy Beyond Day +100 for Late CMV Prevention After Allogeneic Hematopoietic Cell Transplantation. (PubMed, Transplant Cell Ther) - Jul 18, 2026 - "Not applicable." 
Journal • Transplantation
http://www.ncbi.nlm.nih.gov/pubmed/42468826
 
Gonzalo Bentolila; Jonas Mattsson; Nihar Desai
 
Jul 18, 2026
 
Prev Next